Create a management protocol for sepsis in the ICU
Reading File
Finding Sources
Finding Sources
Searching PubMed
"sepsis" AND "surviving sepsis campaign" AND "guidelines"
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Searching PubMed
"sepsis" AND "surviving sepsis campaign" AND "2021"
Here is a comprehensive ICU management protocol for sepsis, synthesized from Harrison's Principles of Internal Medicine (22e), Barash's Clinical Anesthesia (9e), and the 2021 Surviving Sepsis Campaign (SSC) guidelines.
Sepsis & Septic Shock: ICU Management Protocol
1. Definitions (Sepsis-3)
| Term | Criteria |
|---|---|
| Sepsis | Life-threatening organ dysfunction from dysregulated host response to infection; SOFA score increase ≥ 2 from baseline |
| Septic Shock | Sepsis + vasopressor requirement to maintain MAP ≥ 65 mmHg AND lactate > 2 mmol/L despite adequate fluid resuscitation |
| qSOFA (screening) | ≥ 2 of: RR ≥ 22/min, GCS < 15, SBP ≤ 100 mmHg |
2. The Hour-1 Bundle (Immediate Actions)
Act simultaneously on all the following within the first hour of recognition:
- Measure serum lactate — remeasure if initial lactate > 2 mmol/L
- Obtain blood cultures × 2 (before antibiotics, without delaying antibiotics >45 min)
- Administer broad-spectrum IV antibiotics — within 1 hour of septic shock recognition
- IV fluid resuscitation — 30 mL/kg crystalloid for hypotension or lactate ≥ 4 mmol/L
- Start vasopressors if hypotension persists during or after resuscitation to target MAP ≥ 65 mmHg
- ICU admission — target within 6 hours of diagnosis
3. Antimicrobial Therapy
Timing
- Septic shock: antibiotics within 1 hour — each hour of delay increases mortality ~7–8%
- Sepsis without shock: evaluate for up to 3 hours; if no alternate diagnosis, administer empiric antibiotics
Empiric Selection by Source
| Site | Preferred Empiric Regimen |
|---|---|
| CAP | β-lactam (ceftriaxone, ampicillin-sulbactam) + macrolide (azithromycin); or respiratory fluoroquinolone (levofloxacin) |
| HAP/VAP | Vancomycin or linezolid + anti-pseudomonal β-lactam (piperacillin-tazobactam, cefepime, meropenem) |
| Intra-abdominal | Piperacillin-tazobactam or carbapenem; add vancomycin if MRSA risk |
| UTI/urosepsis | Ceftriaxone (community); carbapenem if ESBL risk |
| CNS | Vancomycin + cefepime or meropenem (healthcare-associated meningitis) |
| Undifferentiated (no source) | 3rd-gen cephalosporin (ceftriaxone/cefotaxime) if no Pseudomonas risk; cefepime, pip-tazo, or carbapenem if Pseudomonas suspected |
| MRSA risk | Add vancomycin or linezolid |
| Fungal risk (abdominal surgery, TPN, Candida colonization) | Add echinocandin empirically |
De-escalation
- Reassess daily; narrow based on culture/sensitivity results
- Procalcitonin-guided de-escalation recommended (do not use to withhold antibiotics)
- Typical duration: 7–10 days; reassess per clinical response
Source Control
- Identify and drain/debride all controllable sources (abscess, obstructed biliary tract, bowel perforation, necrotizing fasciitis) as soon as possible
- Remove infected indwelling catheters
4. Hemodynamic Resuscitation
Fluid Management
- Initial bolus: 30 mL/kg IV crystalloid within the first 3 hours
- Preferred fluid: Balanced crystalloids (Lactated Ringer's preferred over normal saline to reduce hyperchloremic acidosis)
- Albumin: Consider when large volumes of crystalloid are required
- Avoid: Hetastarch (HES) — associated with renal injury and increased mortality
- Reassess fluid responsiveness with dynamic indices (pulse pressure variation, passive leg raise, stroke volume variation) rather than CVP
- Serial lactate monitoring guides adequacy of resuscitation; target lactate normalization
Vasopressors
| Agent | Role | Notes |
|---|---|---|
| Norepinephrine | First-line | Target MAP ≥ 65 mmHg |
| Vasopressin | Add-on to NE | Fixed-dose 0.03 U/min; add when NE reaches 0.25–0.5 µg/kg/min to spare NE dose; do not use as sole vasopressor |
| Epinephrine | Third-line | Add when hypotension persists despite NE + vasopressin |
| Dobutamine | Cardiogenic component | Add to NE (or use epinephrine alone) for persistent low cardiac output despite adequate volume |
| Dopamine | Avoid (generally) | Use only in highly selected cases (e.g., severe bradycardia) |
| Levosimendan / Terlipressin | Not recommended |
Targeting supranormal oxygen delivery is not recommended.
Hemodynamic Monitoring
- Arterial line for continuous blood pressure monitoring
- Echocardiography (TTE/TEE) preferred over PA catheter for dynamic ventricular function assessment
- Pulmonary artery catheter: not routinely recommended
5. Corticosteroids
- Indication: Septic shock refractory to adequate fluids and vasopressors
- Regimen: Hydrocortisone 200 mg/day IV (50 mg q6h or 200 mg continuous infusion)
- Do not use corticosteroids if hemodynamic stability can be restored with fluid + vasopressors alone
6. Respiratory Support
Oxygen & Airway
- Supplemental O₂ targeting SpO₂ ≥ 94%
- Early intubation if respiratory failure or inability to protect airway
Mechanical Ventilation — Lung-Protective Strategy (Sepsis-Induced ARDS)
| Parameter | Target |
|---|---|
| Tidal volume | 6 mL/kg of predicted body weight |
| Plateau pressure | ≤ 30 cmH₂O |
| PEEP | Titrated to optimize oxygenation; higher PEEP for moderate-severe ARDS |
| FiO₂ | Lowest to achieve SpO₂ ≥ 88–95% |
| Prone positioning | ≥ 12 hours/day for moderate-severe ARDS (PaO₂/FiO₂ < 150) |
| Neuromuscular blockade | Use to facilitate proning; intermittent bolus preferred over continuous infusion |
| ECMO | Consider for severe ARDS failing mechanical ventilation (experienced center only) |
Ventilator Liberation
- Use weaning protocols with daily sedation interruption
- Spontaneous breathing trials (SBT) when hemodynamically stable
7. Organ-Specific Support
Renal
- Target euvolemia; avoid prolonged positive fluid balance
- Renal replacement therapy (RRT) when refractory hyperkalemia, acidosis, or fluid overload
- IV sodium bicarbonate for arterial pH < 7.2 in AKI
Hematologic
- Transfuse RBCs for Hgb < 7 g/dL (target 7–9 g/dL) in absence of active ischemia or hemorrhage
- DVT prophylaxis (LMWH preferred; mechanical if anticoagulation contraindicated)
Glycemic Control
- Target blood glucose < 180 mg/dL using IV insulin protocol
- Avoid hypoglycemia; monitor blood glucose every 1–2 hours initially
Gastrointestinal
- Stress ulcer prophylaxis (PPI or H₂ blocker) in high-risk patients (coagulopathy, mechanical ventilation)
- Early enteral nutrition if hemodynamically stable (within 24–48 hours)
Sedation & Analgesia
- Analgesia-first approach; titrate sedation to lightest level tolerated
- Preferred: short-acting agents (propofol, dexmedetomidine); avoid benzodiazepines when possible
- Daily sedation interruption ("awakening trials")
8. Monitoring & Targets
| Parameter | Target |
|---|---|
| MAP | ≥ 65 mmHg |
| Serum lactate | ≤ 2 mmol/L (clearance ≥ 10% per 2 hours) |
| Urine output | ≥ 0.5 mL/kg/hour |
| SpO₂ | ≥ 94% |
| Blood glucose | < 180 mg/dL |
| Hemoglobin | 7–9 g/dL |
| Temperature | Treat fever; antipyretics for comfort |
9. Supportive & Adjunctive Care
- Head-of-bed elevation 30–45° (reduces VAP risk)
- Early mobilization when hemodynamically stable
- Remove unnecessary central lines, urinary catheters promptly
- Oral care and chlorhexidine for VAP prevention
- Goals of care discussions early with patient/family; integrate palliative care principles
- Vitamin C / thiamine: not currently recommended as routine (no proven mortality benefit)
- Activated protein C / antithrombin III / IVIG / polymyxin B hemoperfusion: not recommended
10. De-escalation & Discharge Planning
- Discontinue vasopressors when hemodynamically stable off support
- Reassess antibiotic need daily; stop when infection resolved
- Discharge planning includes screening for economic/social support and follow-up for:
- Physical sequelae: fatigue, muscle weakness, functional impairment
- Cognitive sequelae: cognitive decline, depression (post-intensive care syndrome/PICS)
- Cardiovascular risk: increased MI and stroke risk post-sepsis
Key References
- Harrison's Principles of Internal Medicine, 22e — Sepsis & Septic Shock chapter
- Barash's Clinical Anesthesia, 9e — Table 57-4: Management of Sepsis and Septic Shock
- Evans L, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49:e1063 (PMID cited in Harrison's)
- Singer M, et al. Sepsis-3 Definitions. JAMA. 2016;315:801 (PMID: reference standard)
- Recent 2025 update: S3 German Guideline on Sepsis (PMID: 40824313) and ESICM Circulatory Shock Guidelines 2025 (PMID: 41236566)
---This protocol covers the full arc of ICU sepsis management. A few practical points worth highlighting:
Antibiotic timing is the highest-yield intervention — every hour of delay in septic shock costs ~7–8% in mortality. Draw cultures fast, but do not let cultures delay antibiotics.
Fluid resuscitation is not unlimited — the initial 30 mL/kg crystalloid is a starting point. Reassess with dynamic indices (PLR, PPV, SVV) after each bolus. Persistent positive fluid balance worsens outcomes.
Vasopressor ladder: NE → add vasopressin (when NE ≥ 0.25 µg/kg/min) → add epinephrine → add dobutamine if cardiogenic component suspected.
Corticosteroids are reserved for refractory shock, not routine use.
2025 update note: The ESICM published new circulatory shock and hemodynamic monitoring guidelines in 2025 (PMID 41236566) and a German S3 guideline update (PMID 40824313) — these may refine specific targets. The next full SSC guideline update (post-2021) should be checked for any changes to fluid strategy and vasopressor thresholds.
This is a shared conversation. Sign in to Orris to start your own chat.